Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Floxuridine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | TK1 | P04183 | 3/20 | 0.73 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.72 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.72 |
| ▸ | TK2 | O00142 | 1/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.66 |
| ▸ | TSHR | P16473 | 1/20 | 0.66 |
| ▸ | BLM | P54132 | 1/20 | 0.66 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.66 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Floxuridine SCHEMBL18561102 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2TK1ALOX12ADRA1A | |
| Floxuridine SCHEMBL6270910 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2TK1ALOX12ADRA1A | |
| Floxuridine SCHEMBL13674187 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2TK1ALOX12ADRA1A | |
| Floxuridine SCHEMBL18573179 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2TK1ALOX12ADRA1A | |
| Floxuridine SCHEMBL17229 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2TK1ALOX12ADRA1A | |
| Floxuridine SCHEMBL4939702 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2TK1ALOX12ADRA1A | |
| Floxuridine SCHEMBL11564431 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2TK1ALOX12ADRA1A | |
| Floxuridine SCHEMBL2050487 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2TK1ALOX12ADRA1A | |
| Floxuridine SCHEMBL11563300 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2TK1ALOX12ADRA1A | |
| Floxuridine SCHEMBL18597573 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2TK1ALOX12ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-5059088-A | — | — | None | — | — | JP | disclosed |
| US-10933075-B2 | Materials and methods for suppressing and/or treating bacterial infections and related symptoms | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2021-03-02 | — | — | US | disclosed |
| US-20190038648-A1 | MATERIALS AND METHODS FOR SUPPRESSING AND/OR TREATING BACTERIAL INFECTIONS AND RELATED SYMPTOMS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2019-02-07 | — | — | US | disclosed |
| US-5449664-A | Nucleosides | SYNTEX (U.S.A.) INC. (US) | 1995-09-12 | — | — | US | disclosed |
| JP-H0559088-A | PRODUCTION OF 2'-DEOXY-5-FLUORO-BETA-URIDINE | JAPAN TOBACCO INC | 1993-03-09 | — | — | JP | disclosed |
| EP-0457326-A1 | Antiviral agents | SYNTEX (U.S.A.) INC. (US) | 1991-11-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10933075-B2 | Materials and methods for suppressing and/or treating bacterial infections and related symptoms | ELANE, MMP8, LRBA | LMNA 2611/4885SMN1; SMN2 1719/4885TK1 4071/4885 |
| US-20190038648-A1 | MATERIALS AND METHODS FOR SUPPRESSING AND/OR TREATING BACTERIAL INFECTIONS AND RELATED SYMPTOMS | ELANE, MMP8, LRBA | LMNA 2611/4885SMN1; SMN2 1719/4885TK1 4071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.